Coexistence of Leprosy and T-Cell Lymphoma in a 49-Year-Old Female

Lian  C. Jamisola,; Tifany  P. Que,; Sharon Margaret  V. Wong,; Cindy Jao  Tan,; Camille  Berenguer-Angeles,

Coexistence of Leprosy and T-Cell Lymphoma in a 49-Year-Old Female

Tifany P. Que | Sharon Margaret V. Wong | Cindy Jao Tan | Camille Berenguer-Angeles | Lian C. Jamisola

Abstract:

Introduction The occurrence of malignant tumors associated with leprosy has been observed, with lymphoma being the most commonly associated non-epithelial malignant tumor and may be due to the depressed immunologic surveillance. The converse where leprosy manifests in a lymphoma patient undergoing chemotherapy has also been mentioned in a few articles. Case Summary A 49-year-old female was diagnosed to have peripheral T-cell lymphoma after an initial presentation of enlarged lymph nodes, generalized asymptomatic papules and plaques on the trunk, and pancytopenia. Two weeks after initiation of chemotherapy with cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP), her skin lesions progressed to become violaceous to slightly hyperpigmented. Further query revealed a year-long history of hypoesthesia of the lower extremities. Histopathologic examination revealed nodular histiolymphocytic infltrates surrounding blood vessels, adnexal structures, and nerves, consistent with lepromatous leprosy. Fite-Faraco stain was positive. Due to lymphoma-related pancytopenia, the patient was given monthly rifampicin, ofoxacin and minocycline (ROM) chemotherapy, alternatively. Erythema nodosum leprosum reaction developed for which clofazimine was given, resulting in improvement. Conclusion Leprosy is a great mimicker and dermatologists need to be adept at diagnosing skin conditions in immunocompromised patients, especially since disease course and manifestation may be modifed in this subset of patients. Leprosy must be considered when granulomatous lesions arise in lymphoma patients before ascribing them to the underlying disease. Management may also be challenging due to the comorbidities, which may limit treatment options. Careful history, clinical clues, histopathologic correlation, and prudent therapeutic approach are important tools in addressing these cases.

References:

1. Brickner Hans. Interpretation of granulomatous lesions in malignancy. Acta Oncol 1992; 31(1): 85-9.

2. Global leprosy update, 2017: reducing the disease burden due to leprosy. WHO Weekly Epidemiological Record 2018; 93(35): 444–56.

3. Goldsmith LA, Katz SI, Gilchrest BA, Paller SA, Leffell DJ, Wolff K. Fitzpatrick’s Dermatology in General Medicine 8th ed. New York: McGraw-Hill. 2012.

4. Longo LL, Kasper DL, Fauci AS, Hauser SL, Jameson JL, Loscalzo J. Harrison’s Principles of Internal Medicine 18th ed. New York: McGraw-Hill Companies, Inc. 2011.

5. Batsakis JG, ed. Tumors of the Head and Neck: Clinical and Pathological Considerations 2nd ed. Baltimore: Williams and Wilkins. 1979.

6. Paz CJ, Medina IR, Ventura ER. A multidisciplinary study of stigma among the Tausug in the Philippines. Phil Soc Sci Rev 1997; 67.

7. Leprosy control and the burden of leprosy in the Philippines 2006-2010 [Internet]. Retrieved from http://www.wpro.who.int/philippines/areas/communicable_diseases/leprosy/who_leprosy_control_burden

8. Levi MI, Rosen T, Tschen J, Mc Gavran MH, Kalter DC. Hansen’s disease following lymphoma. J Am Acad Dermatol 1986; 15: 204-8.

9. S u j i t a M , Je n o u r i G, H o l d e n M D, D a n i e l s J C. Lepromatous leprosy in a patient with B-cell Lymphoma and Tubulointerstitial Nephritis [Internet]. Hospital Physician 1999 Sept; 51-4. Retrieved from http://www.turnerwhite.com/pdf/hp_jan99_leprosy.pdf

10. Rao S, Jan NM, Sobti P, Khurana N, Garg VK, Jain S. Anaplastic large cell lymphoma and lepromatous leprosy: A rare coexistence. Leprosy Rev 2012; 83: 104–7.

11. Purtilo DT, Pangi C. Incidence of cancer in patients with leprosy. Cancer 1975; 35(4): 1259-61.

12. Brinton LA, Hoover R, Jacobson RR, Frauemeni JF. Cancer mortality among patients with Hansen’s disease.J Natl Cancer Inst 1984; 72(1); 109–14. Retrieved from: https://doi.org/10.1093/jnci/72.1.109

13. Grossman D, Rapini RP, Osborne B, Duvuc M. Emergence of leprosy in a patient with mycosis fungoides. J Am Acad Dermatol 1994; 30: 313-5.

14. Rios L, Azevedo L, Guedes R, Pinto A, Costa P, Varela P, Costa H. Cutaneous B cell lymphoma in a patient with leprosy. Eur J Plast Surg 2013; 36: 119–24

15. Park AJ, Rendini T, Martiniuk F, Levis WR. Leprosy as a model to understand cancer immunosurveillance and Tcell anergy. J Leukoc Biol 2016; 100: 47-54.

16. Oelnick A. Altered immunity and cancer risk: A review of the problem and analysis of the cancer mortality experience of leprosy patients. J Natl Cancer Inst 1969; 43: 775-81.

17. Kolonel LN, Hirohata T. Leprosy and cancer: A retrospective cohort study I Hawaii. J Natl Cancer Inst 1977; 58: 1577-81.

18. Rodriguez E, de Bonaparte YP, Morgenfeld MC, Cabrini RL. Malignant lymphoma in leprosy patients, a clinical and histopathologic study. Int J Lepr 1968; 36: 203-12.

19. McPherson R A, Pincus M R. Henry’s Clinical Diagnosis and Management by Laboratory Methods 22nd ed. Philadelphia: Elsevier Saunders. 2011.

20. Chan GP, ed. A Training Manual and Atlas for the Diagnosis and Treatment of Leprosy and Common Leprosy Look-alike Skin Diseases for Primary Health Care Providers 2nd ed. National Library of the Philippines: GPC Publishing. 2011.

21. Chambers JA, Baffi CW, Nash KT. The diagnostic challenge of Hansen’s disease. Mil Med 2009; 174(6): 652-6.

22. Van Veen NHJ, Nicholls PG, Smith WCS, Hendrik JR. Corticosteroids for treating nerve damage in leprosy: A Cochrane review. Leprosy Rev 2008; 79: 361–71.